Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Saving vision: expanding use of lentiviral gene therapy to fight blindness

Project description

Pioneering gene therapy to restore sight

Vision loss affects hundreds of millions of people worldwide, and for many with genetic eye diseases, treatment remains out of reach. One such condition, Usher syndrome type 1B, causes deafness, balance problems, and blindness due to mutations in the MYO7A gene. The ERC-funded EuroVision project aims to change that. Building on breakthrough research from previous ERC projects, the team has developed a lentiviral gene therapy capable of delivering healthy copies of MYO7A directly to eye cells. Now entering pre-clinical development, this therapy could become the first single-vector treatment for this devastating condition, offering hope to patients and setting the stage for tackling other inherited eye diseases.

Objective

Sight is the most treasured of our senses, followed by hearing and balance. Moderate to severe vision loss affects more than 216 million people worldwide, with an estimated 36 million people suffering from blindness. Monogenic diseases caused by mutations in genes such as MYO7A are responsible for vision loss in over two million people. As current treatment options for genetic vision loss are limited or non-existent, there is a high clinical need for innovative approaches, such as gene therapy. Usher syndrome type 1B (USH1B) is caused by MYO7A mutations and patients suffer from profound deafness accompanied with loss of balance and vision. In my ERC-funded consolidator grant iHEAR and Proof-of-Concept grant MY(O)SENSES, we showed the first ground-breaking data for efficient gene transfer with lentiviral vectors into inner ear cell types and correction of hearing and balance defects caused by mutated MYO7A. The EuroVision PoC proposal aims to advance these valuable research results towards clinical application by completing pre-clinical development, securing IP rights and commercializing a formulated medicinal product to launch a first-in-human clinical LV gene therapy trial to treat USH1B patients. The EuroVision product will be the first and only single-vector treatment that addresses vision loss due to MYO7A mutations in USH1B patients, which has great potential to significantly improve quality of life for these patients as well as to benefit society through relief of costs associated with healthcare and lost productivity. Moreover, this ground-breaking therapy will lay the basis to address other monogenic eye diseases, in which large genes need to be transferred and for which there is an urgent medical need.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

HANNOVER CLINICAL TRIAL CENTER GMBH
Net EU contribution
€ 150 000,00
Address
CARL NEUBERG STR 1 K 27 OE 9751
30625 Hannover
Germany
Region
Niedersachsen Hannover Region Hannover
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)